Guanfacinum [Inn-Latin] en es it fr

Guanfacinum [Inn-Latin] Brand names, Guanfacinum [Inn-Latin] Analogs

Guanfacinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Guanfacinum [Inn-Latin] Chemical_Formula


Guanfacinum [Inn-Latin] RX_link

Guanfacinum [Inn-Latin] fda sheet

Guanfacinum [Inn-Latin] msds (material safety sheet)

Guanfacinum [Inn-Latin] Synthesis Reference

J. B. Bream, C.W. Coward et al.; U.S. Pat. 3,632,645 (1972)

Guanfacinum [Inn-Latin] Molecular Weight

246.093 g/mol

Guanfacinum [Inn-Latin] Melting Point

225-227 oC

Guanfacinum [Inn-Latin] H2O Solubility

1892 mg/L

Guanfacinum [Inn-Latin] State


Guanfacinum [Inn-Latin] LogP


Guanfacinum [Inn-Latin] Dosage Forms

Tablet (oral)

Guanfacinum [Inn-Latin] Indication

For use in the management of hypertension.

Guanfacinum [Inn-Latin] Pharmacology

Similar to clonidine, guanfacine is a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension.

Guanfacinum [Inn-Latin] Absorption

Rapid and complete, with an oral bioavailability of approximately 80%.

Guanfacinum [Inn-Latin] side effects and Toxicity

Symptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD50=165mg/kg (orally in mice)

Guanfacinum [Inn-Latin] Patient Information

Patients who receive guanfacine should be advised to exercise caution when operating dangerous machinery or driving motor vehicles until it is determined that they do not become drowsy or dizzy from the medication. Patients should be warned that their tolerance for alcohol and other CNS depressants may be diminished. Patients should be advised not to discontinue therapy abruptly.

Guanfacinum [Inn-Latin] Organisms Affected

Humans and other mammals